Knotnerus Tim Jasper
Known title: Chief Executive OfficerCIK: 0002120886
Knotnerus Tim Jasper's purchase track record
Knotnerus Tim Jasper has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/5/2026 | AGMB | $94K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AGMB | ▲ Buy | Open Market | 5,000 | $44K | 10/6/2026 | View on chart |
| AGMB | ▲ Buy | Open Market | 6,000 | $51K | 10/5/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Agomab Reports Favorable Safety Data in Phase 2A Crohn's Trial
Agomab Therapeutics shared results from the 48-week open-label extension of its Phase 2A STENOVA trial for severe Crohn's disease. The company noted that the safety and tolerability profile of ontunisertib remained favorable through up to 60 weeks of treatment. Additionally, the annualized rate of FSCD-related events was reported at 3%. This clinical update provides context for the stock's current trading levels near its 52-week low.
Agomab Reports Favorable Safety Data in Phase 2A Crohn's Trial. Agomab Therapeutics shared results from the 48-week open-label extension of its Phase 2A STENOVA trial for severe Crohn's disease. The company noted that the safety and tolerability profile of ontunisertib remained favorable through up to 60 weeks of treatment. Additionally, the annualized rate of FSCD-related events was reported at 3%. This clinical update provides context for the stock's current trading levels near its 52-week low.